Sourya Shrestha1, Andrew N Hill2, Suzanne M Marks2, David W Dowdy1. 1. 1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and. 2. 2 Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
RATIONALE: There is substantial state-to-state heterogeneity in tuberculosis (TB) in the United States; better understanding this heterogeneity can inform effective response to TB at the state level, the level at which most TB control efforts are coordinated. OBJECTIVES: To characterize drivers of state-level heterogeneity in TB epidemiology in the four U.S. states that bear half the country's TB burden: California, Florida, New York, and Texas. METHODS: We constructed an individual-based model of TB in the four U.S. states and calibrated the model to state-specific demographic and age- and nativity-stratified TB incidence data. We used the model to infer differences in natural history of TB and in future projections of TB. MEASUREMENTS AND MAIN RESULTS: We found that differences in both demographic makeup (particularly the size and composition of the foreign-born population) and TB transmission dynamics contribute to state-level differences in TB epidemiology. The projected median annual rate of decline in TB incidence in the next decade was substantially higher in Texas (3.3%; 95% range, -5.6 to 10.9) than in California (1.7%; 95% range, -3.8 to 7.1), Florida (1.5%; 95% range, -7.4 to 14), and New York (1.9%; 95% range, -6.4 to 9.8). All scenarios projected a flattening of the decline in TB incidence by 2025 without additional resources or interventions. CONCLUSIONS: There is substantial state-level heterogeneity in TB epidemiology in the four states, which reflect both demographic factors and potential differences in the natural history of TB. These differences may inform resource allocation decisions in these states.
RATIONALE: There is substantial state-to-state heterogeneity in tuberculosis (TB) in the United States; better understanding this heterogeneity can inform effective response to TB at the state level, the level at which most TB control efforts are coordinated. OBJECTIVES: To characterize drivers of state-level heterogeneity in TB epidemiology in the four U.S. states that bear half the country's TB burden: California, Florida, New York, and Texas. METHODS: We constructed an individual-based model of TB in the four U.S. states and calibrated the model to state-specific demographic and age- and nativity-stratified TB incidence data. We used the model to infer differences in natural history of TB and in future projections of TB. MEASUREMENTS AND MAIN RESULTS: We found that differences in both demographic makeup (particularly the size and composition of the foreign-born population) and TB transmission dynamics contribute to state-level differences in TB epidemiology. The projected median annual rate of decline in TB incidence in the next decade was substantially higher in Texas (3.3%; 95% range, -5.6 to 10.9) than in California (1.7%; 95% range, -3.8 to 7.1), Florida (1.5%; 95% range, -7.4 to 14), and New York (1.9%; 95% range, -6.4 to 9.8). All scenarios projected a flattening of the decline in TB incidence by 2025 without additional resources or interventions. CONCLUSIONS: There is substantial state-level heterogeneity in TB epidemiology in the four states, which reflect both demographic factors and potential differences in the natural history of TB. These differences may inform resource allocation decisions in these states.
Entities:
Keywords:
geographical heterogeneity in tuberculosis; mathematical modeling of tuberculosis; tuberculosis; tuberculosis in the United States
Authors: C Robert Horsburgh; Max O'Donnell; Sandra Chamblee; Janet L Moreland; Johnny Johnson; Bryan J Marsh; Masahiro Narita; Linda Scoles Johnson; C Fordham von Reyn Journal: Am J Respir Crit Care Med Date: 2010-04-15 Impact factor: 21.405
Authors: Laith J Abu-Raddad; Lorenzo Sabatelli; Jerusha T Achterberg; Jonathan D Sugimoto; Ira M Longini; Christopher Dye; M Elizabeth Halloran Journal: Proc Natl Acad Sci U S A Date: 2009-08-03 Impact factor: 11.205
Authors: den Bosch J H Wolleswinkel-van; N J D Nagelkerke; J F Broekmans; M W Borgdorff Journal: Int J Tuberc Lung Dis Date: 2002-02 Impact factor: 2.373
Authors: Kimberly M Shea; J Steve Kammerer; Carla A Winston; Thomas R Navin; C Robert Horsburgh Journal: Am J Epidemiol Date: 2013-10-18 Impact factor: 4.897
Authors: Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Andrea Parriott; James G Kahn; Haleh Ashki; Adam Readhead; Pennan M Barry; Alex J Goodell; Jennifer Flood; Priya B Shete Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Sourya Shrestha; Sarah Cherng; Andrew N Hill; Sue Reynolds; Jennifer Flood; Pennan M Barry; Adam Readhead; Margaret Oxtoby; Michael Lauzardo; Tom Privett; Suzanne M Marks; David W Dowdy Journal: Am J Epidemiol Date: 2019-09-01 Impact factor: 4.897
Authors: Nicolas A Menzies; Ted Cohen; Andrew N Hill; Reza Yaesoubi; Kara Galer; Emory Wolf; Suzanne M Marks; Joshua A Salomon Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 4.897
Authors: Sarah T Cherng; Sourya Shrestha; Sue Reynolds; Andrew N Hill; Suzanne M Marks; Jane Kelly; David W Dowdy Journal: Am J Public Health Date: 2018-11 Impact factor: 9.308
Authors: Nicolas A Menzies; Andrea Parriott; Sourya Shrestha; David W Dowdy; Ted Cohen; Joshua A Salomon; Suzanne M Marks; Andrew N Hill; Carla A Winston; Garrett R Asay; Pennan Barry; Adam Readhead; Jennifer Flood; James G Kahn; Priya B Shete Journal: Am J Respir Crit Care Med Date: 2020-02-01 Impact factor: 21.405